Genmab — Marts 2021
-
9,57 Stock. Med Genmab har jeg købt i 2075, 2045, 2033 og i 1901,5. Jeg var ude i nogle måneder, men begyndte altså igen. Har trådet den meget. En anden er ZEAL som jeg har ligget passivt i fra 2015. Her. kunne jeg også have solgt i 290, men gjorde det ikke og nu er den i 190. To forskellige strategier. Så må vi se. Kunne være spændende med et tilsvarende skema over ZEAL, som du har lavet i GEN.
-
Jeg kan anbefale trading view https://video-ideas.tradingview.com/2/2532952-66FZK1SaAuORRTGC.mp4 hvor man kan finde en det tips til at finde potentielle vindere
-
does this guy say anything usefull? https://ugebrev.dk/flashnews/langers-skarpe-her-er-forklaringen-paa-ugens-blodbad-i-danske-aktier/
-
ØU/David Mygind 4/3.: "Samlet betyder forventningerne til udviklingen i pipelinen, at vi bibeholder en kort tidshorisont på 6 måneder for vores reducerede kursmål på 2500 DKK, som i skrivende stund giver et potentiale på 30%, hvilket retfærdiggør, at vi opretholder en stærk købsanbefaling.
Kurs på anbefalingstidspunkt 1.925 DKK
Kursmål (6 mdr.) 2.500 DKK
-
"Vi vælger dog for nuværende at afvente data, før vi finder det relevant at justere vores værdiansættelsesmodel. I mellemtiden vælger vi at fratrække en midlertidig arbitrær kursmålsrabat på 100 DKK, som relaterer sig til de højere omkostninger og den negative indflydelse, det for nuværende har på aktiekursen.
Endelig vælger vi også at fratrække 100 DKK yderligere fra vores kursmål som en refleksion af, at voldgiftssagen trækker ud, alt imens Genmab allerede nu realiserer et royalty-tab".
-
ungee...Artiklen er låst. Jeg har skrevet til ØU om at åbne den. Vores aftale er, at "Langers Skarpe" hver lørdag er åben for vore brugere.
-
"Langers Skarpe" er åben nu. https://www.proinvestor.com/investornyt/672839/langers-skarpe-her-er-forklaringen-pa-ugens-blodbad-i-danske-aktier
-
Mygind notes that higher/ faster investments mean some extra risk. I had not realised people would think that way? I would argue that Genmab decides how to proceed after each development phase with each additional data point they get. To get to that data point they need to do an investment, the size of which will not depend much on the speed they get there.
-
To me it is clear that, IF there is an adverse event in one of the projects, they will stop the development and therefore not use the full budget for that project. Whether you get there slow or fast. They recently showed their discipline in cutting development in Enapotamab and, in a sense, also with Camidanlumab.
-
Genmab could have also chosen to guide initially with lower costs and increase guidance after each successfully finished development phase. As is said before, to me, budgetting the fast development already now, shows conviction that they think that their projects will be successful.
Ligesom Vestas Appel osv osv
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind